tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

KNSA Stock Latest News

Kiniksa price target raised to $42 from $30 at Wells Fargo
The FlyKiniksa price target raised to $42 from $30 at Wells Fargo
1h ago
KNSA
Kiniksa Pharmaceuticals Unveils Phase 2/3 Trial Plans
PremiumCompany Announcements
Kiniksa Pharmaceuticals Unveils Phase 2/3 Trial Plans
1M ago
8K
KNSA
Kiniksa announces details for planned 2/3 trial of KPL-387
PremiumThe Fly
Kiniksa announces details for planned 2/3 trial of KPL-387
1M ago
KNSA
Kiniksa Pharmaceuticals Annual Shareholders Meeting Decisions
PremiumCompany Announcements
Kiniksa Pharmaceuticals Annual Shareholders Meeting Decisions
1M ago
8K
KNSA
Kiniksa Pharmaceuticals Q1 2025 Earnings: Strong Growth
PremiumCompany Announcements
Kiniksa Pharmaceuticals Q1 2025 Earnings: Strong Growth
2M ago
KNSA
Kiniksa announces Carly Pearce joined the Life DisRPted Campaign
PremiumThe FlyKiniksa announces Carly Pearce joined the Life DisRPted Campaign
2M ago
KNSA
Kiniksa Pharmaceuticals Reports Strong Q1 2025 Growth
Premium
Company Announcements
Kiniksa Pharmaceuticals Reports Strong Q1 2025 Growth
2M ago
KNSA
Kiniksa price target raised to $45 from $40 at Jefferies
Premium
The Fly
Kiniksa price target raised to $45 from $40 at Jefferies
2M ago
KNSA
Kiniksa reports Q1 EPS 11c, consensus 28c
PremiumThe Fly
Kiniksa reports Q1 EPS 11c, consensus 28c
2M ago
KNSA
Kiniksa sees FY25 ARCALYST net product revenue $590M-$605M
PremiumThe Fly
Kiniksa sees FY25 ARCALYST net product revenue $590M-$605M
2M ago
KNSA
Kiniksa Pharmaceuticals Approves Long-Term Incentive Plan
PremiumCompany Announcements
Kiniksa Pharmaceuticals Approves Long-Term Incentive Plan
3M ago
8K
KNSA
Kiniksa initiated with a Buy at Citi
PremiumThe Fly
Kiniksa initiated with a Buy at Citi
4M ago
KNSA
Kiniksa Pharmaceuticals Reports Strong Growth Amid Challenges
PremiumCompany AnnouncementsKiniksa Pharmaceuticals Reports Strong Growth Amid Challenges
4M ago
KNSA
Kiniksa price target lowered to $30 from $35 at Wells Fargo
Premium
The Fly
Kiniksa price target lowered to $30 from $35 at Wells Fargo
4M ago
KNSA
Buy Rating for Kiniksa Pharmaceuticals Driven by Strategic Refocus and Commercial Success
Premium
Ratings
Buy Rating for Kiniksa Pharmaceuticals Driven by Strategic Refocus and Commercial Success
4M ago
KNSA
Kiniksa Pharmaceuticals: Strategic Focus on Cardiovascular Growth and Stability Underpins Buy Rating
PremiumRatings
Kiniksa Pharmaceuticals: Strategic Focus on Cardiovascular Growth and Stability Underpins Buy Rating
4M ago
KNSA
Kiniksa Pharmaceuticals Reports Strong ARCALYST Growth
PremiumCompany Announcements
Kiniksa Pharmaceuticals Reports Strong ARCALYST Growth
4M ago
KNSA
Kiniksa Pharmaceuticals Ends License Agreement with MedImmune
PremiumCompany Announcements
Kiniksa Pharmaceuticals Ends License Agreement with MedImmune
4M ago
8K
KNSA
Kiniksa reports Q4 EPS (12c), consensus 13c
PremiumThe Fly
Kiniksa reports Q4 EPS (12c), consensus 13c
4M ago
KNSA
Kiniksa sees FY25 ARCALYST net product revenue $560M-$580M
PremiumThe FlyKiniksa sees FY25 ARCALYST net product revenue $560M-$580M
4M ago
KNSA
Kiniksa announces development of KPL-387, updated corporate strategy
Premium
The Fly
Kiniksa announces development of KPL-387, updated corporate strategy
4M ago
KNSA
Kiniksa to discontinue development of abiprubart in Sjogren’s Disease
Premium
The Fly
Kiniksa to discontinue development of abiprubart in Sjogren’s Disease
4M ago
KNSA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >